Chikungunya is caused by infection with chikungunya virus (CHIKV), a positive-sense single-stranded RNA virus in the family Togaviridae, genus Alphavirus. Transmission occurs via the bite of infected mosquitoes; the disease is not caused by germline genetic variants or inherited through family pedigrees. No host genetic risk factors are documented in this packet.

Diagnosis of chikungunya is typically based on clinical presentation in the context of known CHIKV exposure or travel to endemic regions, confirmed by laboratory testing including viral RNA detection by reverse transcription-PCR during the early febrile phase and serology (IgM and IgG antibody testing) in later stages. Differential diagnosis includes dengue fever and Zika virus infection. No genetic testing is applicable to this diagnosis.

No approved pharmacologic treatments specific to chikungunya are documented in this packet. Management in published literature has focused on symptomatic relief of fever and joint pain; no antiviral therapy has been approved as of this packet's data. Research into vaccines and antiviral compounds is ongoing.

The acute phase of chikungunya is self-limiting in most individuals. However, arthralgia can persist for months or longer in a proportion of cases, representing a significant source of morbidity. Specific natural history or outcome data are not available in this packet.

Several active clinical trials registered with ClinicalTrials.gov are evaluating chikungunya vaccine candidates and long-term safety monitoring. Studies include Phase 3 and observational follow-up protocols assessing immunogenicity and safety of CHIKV vaccination in various populations, reflecting active investment in preventive strategies.